Blueprint Medicines to advance BLU-285 in Phase 1 trial for systemic mastocytosis
10 September 2015 | By Victoria White
BLU-285 is a potent and highly selective inhibitor of the KIT D816V mutant, the primary driver of disease in more than 94% of systemic mastocytosis patients...